TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A systematic review and meta-analysis of 19 studies involving nearly 15.9 million participants associated ADHD with a 71% higher rate of all-cause mortality than in people without ADHD. ADHD medication use was associated with lower all-cause mortality in three studies, but the authors cautioned that this finding may reflect differences between treated and untreated groups rather than a medication effect.
A systematic review and meta-analysis involving nearly 15.9 million people found that ADHD was associated with a 71% higher rate of all-cause mortality than not having ADHD, according to a study published in JAMA Network Open. The researchers also reported higher rates of suicide, injury and natural-cause mortality, while stressing that the results describe population-level associations, not the outlook for any one person.
Joshua Stott, PhD, of University College London, and colleagues analyzed 19 studies with a combined 15,920,970 participants. Twelve studies supplied results for the meta-analyses. Across nine studies, ADHD was associated with an all-cause mortality hazard ratio of 1.71 (95% confidence interval 1.31 to 2.24). A hazard ratio compares the rate of an outcome over time between groups; it does not directly state an individual’s chance of dying.
The analysis also found higher rates associated with suicide (HR 1.89), intentional or unintentional injury (HR 1.55), and natural causes (HR 1.27). These estimates came from five, four and three studies, respectively. The researchers said all studies showed higher mortality in ADHD groups, though the size of the association varied. Variation across studies was substantial in several analyses, limiting how precisely the pooled estimates can be applied across populations.
A separate analysis of three studies associated ADHD medication use with a 25% lower all-cause mortality rate (HR 0.75; 95% CI 0.64 to 0.87). The authors cautioned that this evidence is limited and may be affected by differences between people who receive medication and those who do not, including healthcare access, illness severity and other health conditions. The study does not establish that medication itself reduces mortality.
Mortality Patterns Point to Care Gaps
The findings draw attention to health risks that may accompany ADHD beyond its effects on attention, organization and daily functioning. The researchers discussed possible pathways, including impulsivity and risk-taking linked to injury, depression and other co-occurring conditions linked to suicide risk, and smoking, alcohol use, cardiovascular disease, metabolic disorders or barriers to care that could contribute to deaths from natural causes. These are potential explanations, not mechanisms proven by this review.
The results may also matter for adults whose ADHD has not been recognized or treated. Study co-author Stott told MedPage Today that the findings support access to accurate diagnosis and treatment for people who may have ADHD. That should not be read as a claim that diagnosis or treatment guarantees a particular health outcome; the study measured associations in existing research, not the effect of a specific care program.
The medication result is especially easy to overstate. Because it relies on only three studies and may be confounded by differences in the people receiving treatment, it cannot establish a protective effect. Further research would be needed to determine whether treatment changes mortality risk and, if so, for whom and through what pathways.
As an affiliate, we earn on qualifying purchases.
How Researchers Combined the Evidence
The team reviewed quantitative research on all-cause or cause-specific mortality in people with ADHD, including studies published through July 2025. ADHD was identified in different ways across the research: through diagnostic criteria, self-identification, measures of ADHD traits or genetic risk scores. Participants covered different age groups and cultural settings, which adds breadth but also means the included studies did not all define or measure ADHD in the same way.
Earlier studies had also reported higher mortality among people with ADHD, and some had suggested a life-expectancy gap. This review combined a larger body of research to estimate associations across outcomes. It included participants who were 63.9% male, and the authors noted gender imbalances in many studies. Differences in diagnostic practices, access to care and study populations are among factors that may help explain variation in the results.
U.S. figures cited in the MedPage Today report provide a sense of how many people could be affected: the CDC estimates that 15 million adults—about 6% of U.S. adults—have ADHD, and that 7 million children ages 3 to 17 have received an ADHD diagnosis. These national estimates are background figures, not measurements made by the meta-analysis.
“These findings do not suggest that everyone with ADHD will die young, nor do they suggest that increased mortality is impossible to change or inherent to ADHD.”
— Joshua Stott, PhD, study co-author, speaking to MedPage Today
adult ADHD organizational planners
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Limits of the Mortality Estimates
The review cannot show that ADHD directly causes higher mortality, or identify how much of the association is explained by co-occurring conditions, social circumstances, access to healthcare or other factors. The studies differed in how they defined ADHD and measured outcomes, and several pooled analyses had substantial heterogeneity. That means the estimated size of the association may not apply equally across ages, settings or groups.
The medication finding is particularly uncertain: it comes from only three studies. The authors said residual confounding and confounding by indication could affect the result; for example, treated and untreated people may differ in health status, treatment access, adherence or psychiatric conditions. The analysis therefore cannot establish that medication lowers mortality. The review also does not determine which interventions would reduce the observed risks or how any effects vary by age, sex or ADHD presentation.
As an affiliate, we earn on qualifying purchases.
Further Studies Needed on Treatment
The next step is additional research that can test the mortality associations in more varied populations and clarify why rates differ. Studies that track treatment and health outcomes over time, while accounting for differences in participants’ health and access to care, could help assess whether ADHD medication is associated with a change in mortality risk or whether the observed link reflects other factors.
For now, the published analysis provides pooled estimates from research available through July 2025; it does not report a new clinical trial or a treatment recommendation. The authors’ call for accurate diagnosis and access to care is a stated implication, while the best ways to address the mortality patterns remain unresolved.
As an affiliate, we earn on qualifying purchases.
Key Questions
Does the study mean a person with ADHD is likely to die young?
No. The study found a higher average mortality rate in groups with ADHD, but it does not predict an individual’s lifespan. Stott explicitly told MedPage Today that the findings do not mean everyone with ADHD will die young.
What mortality outcomes were associated with ADHD?
The meta-analysis reported higher rates of all-cause mortality, suicide, injury and natural-cause mortality among people with ADHD. These are associations drawn from different groups of studies, not proof that ADHD directly caused the deaths.
Did the study prove ADHD medication reduces mortality?
No. Medication use was associated with lower all-cause mortality in an analysis of three studies, but the authors cautioned that differences between treated and untreated people could explain some or all of the association. The result does not prove a medication effect.
How large was the evidence base?
The review included 19 studies and 15,920,970 participants. Twelve studies contributed results to the pooled analyses, and the number varied by outcome.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
